References
- .Wasner K, Klier H, Borasio G. The use of alternative medicine by patients with amyotrophic lateral sclerosis. J Neurol Sci. 2001;191:151–4.
- Bedlack RS, Pastula DM, Welsh E, Pulley D, Cudkowicz M. Scrutinizing enrollment in ALS clinical trials: room for improvement? Amyotroph Lateral Scler. 2008;9:257–65.
- Bedlack RS, Silani V, Cudkowicz M. IPLEX and the telephone game: the difficulty in separating myth from reality on the internet. Amyotroph Lateral Scler. 2009;10:182–4.
- Bedlack, R, Hardiman, O.ALSUntangled (ALSU): A Scientific Approach to Off-Label Treatment Options for People with ALS Using Tweets and Twitters. Amyotroph Lateral Scler. 2009;10:129–30.
- www.alsuntangled.com (cited 11/4/14).
- The ALSUntangled Group. ALSUntangled No. 20: The Deanna Protocol. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:319–23.
- Ari C, Poff A, Held H, Landon C, Goldhagen C, Mavromates N, et al.Metabolic therapy with Deanna Protocol supplementation delays disease progression and extends survival in amyotrophic lateral sclerosis (ALS) mouse model . PLoS One 2014;9:e103526.
- Ludolph A, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler J, et al.Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph Lateral Scler. 2010;11:38–45
- http://ohg.cochrane.org/sites/ohg.cochrane.org/files/uploads/Risk%20of%20bias%20assessment%20tool.pdf. Cited 9/1/14.